Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Classification of common stock other than Class A common stock. Common stock Class A common stock Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Restricted Cash, Current Restricted cash Accounts Receivable, Net, Current Accounts receivable The sum of amounts currently receivable from tax research premium. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. Receivables Tax Research Premium, Current Receivable research incentives Receivable research incentive Amount of asset related to consideration paid in advance for costs and other other current assets. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets Assets, Current Total current assets Assets, Noncurrent [Abstract] Non-current assets: Restricted Cash, Noncurrent Restricted cash Cash balance maintained to secure a letter of credit associated with a real estate lease Property, Plant and Equipment, Net Property, plant and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right of use assets Operating lease right-of-use assets Finance Lease, Right-of-Use Asset Finance lease right of use assets Finance lease right-of-use assets Other Assets, Noncurrent Other non-current assets Assets, Noncurrent Total non-current assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Contract with Customer, Liability, Current Deferred revenues Operating Lease, Liability, Current Current operating lease liability Operating lease liabilities, current Amount of Amount of expenses incurred but not yet paid nor invoiced current, and liabilities classified as other current. Accrued Expenses and Other Current Liabilities. Accrued expenses and other current liabilities Total Loans Payable, Current Loans payable, current Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Non-current liabilities Loans Payable. Loans payable, non-current Operating Lease, Liability, Noncurrent Non-current operating lease liability Operating lease liabilities, non-current Contract with Customer, Liability, Noncurrent Deferred revenues, non-current Other Liabilities, Noncurrent Other non-current liabilities Liabilities, Noncurrent Total non-current liabilities Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 12) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; Series A convertible preferred stock, 2,978 shares designated, 1,697 shares outstanding at September 30, 2022 and December 31, 2021, respectively; Series A-1 convertible preferred stock, 15,800 shares and no shares designated, 15,800 shares and no shares outstanding at September 30, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Common stock Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance at the end of the period Balance at the beginning of the period Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Represents information pertaining to Series A Convertible preferred stock. Series A Convertible Preferred Stock N/A Series A -1 Convertible Preferred Stock Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Total number of shares designated as preferred shares Preferred stock shares Designated Preferred stock shares Designated Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common stock, issued (in shares) Common Stock, Shares, Outstanding Common stock, shares outstanding Common stock, outstanding (in shares) CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Revenue from Contract with Customer, Excluding Assessed Tax Revenue from collaboration and licensing Revenue from Contract with Customer, Product and Service [Extensible List] Operating Expenses [Abstract] Operating expenses: Research and Development Expense. Research and development General and Administrative Expense. General and administrative Operating Costs and Expenses Total operating expenses Operating Income (Loss) Loss from operations Other Nonoperating Income (Expense) [Abstract] Other income (expense): The amount of grant income. Grant Income Grant income Investment Income, Interest Interest income Interest Expense Interest expense Other Nonoperating Income (Expense) Other income and (expenses), net Nonoperating Income (Expense) Total other income, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net loss before tax Income Tax Expense (Benefit) Income tax expense Net Income (Loss) Attributable to Parent Net loss Net loss Net losses Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment, net of tax Foreign currency translation gain (loss), net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic Net loss per share - basic Earnings Per Share, Diluted Net loss per share - diluted CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) Equity Components [Axis] Equity Component [Domain] Represents information pertaining to convertible preferred stocks. Convertible Preferred Stock Common Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Accumulated Deficit Represents information pertaining to Series A-1 convertible preferred stock. Series A-1 convertible preferred stock Sale of Stock [Axis] Sale of Stock [Domain] Sale of stock by a private company to the public. Public offering Public offering Represents information pertaining to stock purchase agreement. Stock Purchase Agreement Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Stock Issued During Period, Value, New Issues Issuance of stock Stock Issued During Period, Shares, New Issues Issuance of stock (in shares) Issuance of common stock Conversion of Stock, Amount Issued Conversion of Class A common stock to common stock Conversion of Stock, Shares Issued Shares issued upon conversion of redeemable convertible preferred stock (in shares) Conversion of Class A common stock to common stock (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Issuance of common stock upon exercise of stock options (in shares) Aggregate value of stock related to Restricted Stock Awards vested during the period. Stock Issued During Period, Value, Restricted Stock Award, Vested Vesting of restricted stock Number of shares related to Restricted Stock Award vested during the period. Stock Issued During Period, Shares, Restricted Stock Award, Vested Vesting of restricted stock (in shares) Value of vested shares granted under share-based payment arrangement. Shares Granted, Value, Share-based Payment Arrangement, Vested Vesting of equity grants Number of shares (or other type of equity) vested during the period. Shares Issued, Shares, Share-based Payment Arrangement, Vested Vesting of equity grants (in shares) Amount of increase decrease to additional paid in capital due to at the market issuance cost. Adjustments to Additional Paid in Capital, At the Market Issuance Cost ATM costs Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Share Price Share price (in USD per share) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Issuance costs CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation expense Stock-based compensation expense Depreciation, Depletion and Amortization Depreciation and amortization expense Other Noncash Income (Expense) Other non-cash items Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable The increase (decrease) during the reporting period in amount of receivable research incentives. Increase (Decrease) in Receivable Research Incentives Receivable research incentives The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods and other current assets. Increase (Decrease) in Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other non-current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Contract with Customer, Liability Deferred revenues Increase (Decrease) in Operating Lease Liabilities Operating lease liabilities The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other liabilities. Increase (Decrease) in Accrued Liabilities and Other Liabilities Accrued expenses and other liabilities Increase (Decrease) in Other Noncurrent Liabilities Other non-current liabilities Net Cash Provided by (Used in) Operating Activities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Finance Lease, Principal Payments Payments related to finance leases Proceeds from Issuance of Convertible Preferred Stock Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Repayments of Debt Repayments of borrowings Principal payment Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Effect of exchange rate changes on cash, cash equivalents and restricted cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Income Taxes Paid, Net Cash paid for income taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash financing activities: Amount of property and equipment additions in accounts payable and accrued expenses. Property and Equipment Additions in Accounts Payable and Accrued Expenses Property and equipment additions in accounts payable and accrued expenses Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Lease assets obtained in exchange for new operating lease liabilities The amount of right of use assets derecognized upon lease cancellation. Lease Assets Derecognized Upon Lease Cancellation Lease assets derecognized upon lease cancellation Nature of the business and organization Nature of Operations [Text Block] Nature of the business and organization Summary of significant accounting policies Significant Accounting Policies [Text Block] Summary of significant accounting policies No definition available. Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Collaboration and Licensing Agreements Fair Value of Financial Assets Fair Value Disclosures [Text Block] Fair Value of Financial Assets Property, plant and equipment, net. Property, Plant and Equipment Disclosure [Text Block] Property, plant and equipment, net n/a. Receivable research incentive The entire disclosure for receivable research incentive. Receivable Research Incentive [Text Block] Receivable research incentive No definition available. Accrued expenses and other current liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued expenses and other current liabilities Loans payable The entire disclosure of loans payable. Disclosure of Long Term Loans Payable [Text block] Loans payable Common stock, Class A common stock and convertible preferred stock Stockholders' Equity Note Disclosure [Text Block] Common stock, Class A common stock and convertible preferred stock Stock-based compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based compensation Income taxes Income Tax Disclosure [Text Block] Income taxes Commitments and contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and contingencies Net loss per share Earnings Per Share [Text Block] Net loss per share Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of presentation Disclosure of accounting policy for going concern. Going Concern, Policy [Policy Text Block] Going concern Use of Estimates, Policy [Policy Text Block] Use of estimates Disclosure of accounting policy for deferred offering costs. Deferred Offering Costs, Policy [Policy Text Block] Deferred offering costs Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations of credit risk and of significant suppliers Cash and Cash Equivalents, Policy [Policy Text Block] Cash equivalents Fair Value Measurement, Policy [Policy Text Block] Fair value measurements Property, Plant and Equipment, Policy [Policy Text Block] Property and equipment Lessee, Leases [Policy Text Block] Leases Research, Development, and Computer Software, Policy [Policy Text Block] Capitalized Software Development Cost Revenue from Contract with Customer [Policy Text Block] Revenue recognition from contracts with customers New Accounting Pronouncements, Policy [Policy Text Block] Recent accounting pronouncements Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Schedule of Property, Plant and Equipment, Useful Life [Table Text Block] Schedule of estimated useful life of each asset Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets measured at fair value on a recurring basis Property, Plant and Equipment [Table Text Block] Schedule of property, plant and equipment, net Tabular disclosure of accrued expenses and other current liabilities. Schedule of Accrued Expenses and Other Liabilities, Current [Table Text Block] Schedule of accrued expenses and other current liabilities Tabular disclosure of loans payable. Disclosure of Long Term Loans Payable [Table Text block] Schedule of loans payable Contractual Obligation, Fiscal Year Maturity [Table Text Block] Schedule of aggregate minimum future principal payments due in connection with the FFG Loans Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used in the Black-Scholes option-pricing model for estimating the fair value of stock options Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of stock option activity Share-based Compensation, Activity [Table Text Block] Schedule of stock-based compensation expense Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities that were not included in the diluted per share calculations Concentration Risk [Table] Concentration Risk [Line Items] Property, Plant and Equipment [Table] Property and equipment, net Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Laboratory equipment Furniture and fixtures Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks. Computer equipment and software Range [Axis] Range [Domain] Minimum Maximum Property, Plant and Equipment [Line Items] Property and equipment Property, Plant and Equipment, Useful Life Estimated useful life (in years) New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Summary of significant accounting policies The number of preclinical research programs in collaborative arrangement. Collaborative Arrangement, Number of Preclinical Research Programs Number of preclinical research programs Number of combined performance obligation for each research program. Number of Combined Performance Obligation for Each Research Program Number of combined performance obligation for each research program Number of research program performance obligations. Number of Research Program Performance Obligations Number of research program performance obligations Collaborative Arrangement and Arrangement Other than Collaborative [Table] Information by characteristics of milestone payments recognized under the milestone method by arrangement. Milestone [Axis] Components of milestones that an entity engage. Milestone [Domain] Represents information pertaining to development milestones. Development Milestones Represents information pertaining to commercial milestones. Commercial Milestones Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Gilead Collaboration and License Agreement HBV program. HBV program HIV program. HIV program Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaboration and Licensing Agreements Represents the number of preclinical research programs. Number of Preclinical Research Programs Number of preclinical research programs The amount of cash inflow from non-refundable upfront payment. Proceeds from Non-Refundable, Up-front Payment Upfront payment received Amount of expenses relating to program initiation fees under collaborative agreement. Collaborative Agreement, Program Initiation Fees Program initiation fee Total milestone amount. Total Milestone Amount Total milestone amount Option exercise payment. Option Exercise Payment Option exercise payment The term for royalty payment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Collaborative Arrangement, Term of Royalty Payment Payment term (in days) The amount received from milestone payment. Proceeds From Milestone Payment Milestone payment received Amount of upfront and milestone payments included as a liability in deferred revenues. Deferred Revenues, Upfront and Milestone Payments Upfront and milestone payments included in deferred revenues Percentage of revenue recognized that was previously reported as deferred or unearned revenue. Deferred Revenue, Percentage of Revenue Recognized, Remainder of Fiscal year Percentage of upfront payment included in deferred revenue expected to be recognized in 2022 Percentage of revenue recognized in year one that was previously reported as deferred or unearned revenue. Deferred Revenue, Percentage of Revenue Recognized in Year One Percentage of upfront payment included in deferred revenue expected to be recognized in 2023 Percentage of revenue recognized in year two that was previously reported as deferred or unearned revenue. Deferred Revenue, Percentage of Revenue Recognized in Year Two Percentage of upfront payment included in deferred revenue expected to be recognized in 2024 Percentage of revenue recognized in year three that was previously reported as deferred or unearned revenue. Deferred Revenue, Percentage of Revenue Recognized in Year Three Percentage of upfront payment included in deferred revenue expected to be recognized in 2025 Amount of cost reimbursements for research and development services included as a liability in deferred revenues. Deferred Revenues, Cost Reimbursements for Research and Development Services Cost reimbursements for research and development services included in deferred revenues The amount of milestone payments revenue recognized under the collaboration agreement. Collaboration Agreement, Milestone Payments, Revenue Recognized Revenue recognized from milestone payments The amount of revenue from cost reimbursements for research and development services. Collaborative Arrangement, Revenue from Cost Reimbursements for Research and Development Services Revenue recognized from cost reimbursements for research and development services Amount of cost reimbursements for research and development services, of which initially recorded as deferred revenue. Collaborative Arrangement Revenue From Cost Reimbursements For Research And Development Services Recorded As Deferred Revenue Revenue recognized from cost reimbursements for research and development services initially recorded as deferred revenue The amount of contract assets relating to sublicense payment. Collaborative Arrangement, Contract Asset Relating to Sublicense Payment Contract asset relating to the sublicense payment Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 1 Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Money market funds Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Assets Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2. Fair Value, Assets, Level 1 to Level 2 Transfers, Amount1 Transfers from Level 1 to Level 2 Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1. Fair Value, Assets, Level 2 to Level 1 Transfers, Amount1 Transfers from Level 2 to Level 1 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Transfers from into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Transfers from out of Level 3 Land Leasehold improvements Construction in progress Property, Plant and Equipment, Gross Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Grant income recognized related to the incentive program during the reporting period. Grant Income, Incentive Program Income related to the incentive program recorded as grant income Accrued Employee Benefits, Current Salaries and bonuses Carrying amount as of the balance sheet date of the unpaid sum of the social security contributions. Accrued Social Security Contributions, Current Social security contributions Carrying amount as of the balance sheet date of accrued unearned grant income (current). Accrued Unearned Grant Income , Current Unearned grant income (current) Amount of accrued sub license fees at the balance sheet date. Accrued Sub License Fees Sublicense fees The carrying amount as of balance sheet date of accrued external research and development expenses. Accrued External Research and Development Expenses Accrued external research and development expenses The carrying amount as of balance sheet date of accrued external general and administration expenses. Accrued External General and Administration Expenses Accrued external general and administration expenses The carrying amount as of balance sheet date of accrued expenses for property and equipment acquisitions. Accrued Expenses for Property and Equipment Acquisitions Accrued for property and equipment acquisitions Finance Lease, Liability, Current Outstanding finance lease obligations Finance lease liabilities Carrying amount as of the balance sheet date of other accruals and liabilities. Other Accrued Expenses and Liabilities, Current Other accruals and liabilities Schedule of Long-term Debt Instruments [Table] Loans payable Debt Instrument [Line Items] Loans payable The amount of loans payable, gross. Long Term Loans Payable, Gross Loans from FFG Debt Instrument, Unamortized Discount, Noncurrent Unamortized debt discount Loans Payable, Noncurrent Total loans payable, net Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Long-term Debt, Fiscal Year Maturity [Abstract] Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2023 Long-term Debt, Maturities, Repayments of Principal in Year Two 2024 Long-term Debt Total Represents information pertaining to Series A and Series A-1 preferred stock . Series A and Series A-1 convertible preferred stock Ownership [Axis] Ownership [Domain] Represents information pertaining Gilead Sciences, Inc. Gilead Preferred Stock, Shares Issued Preferred stock, shares issued Proceeds from Issuance or Sale of Equity Net proceeds from public offering Represents amount remaining common stock reserved for future issuance. Remaining of Common Stock Reserved for Future Issuance Outstanding amount Represents premium percentage on volume weighted average purchase price of shares. Premium Percentage on Volume Weighted Average Purchase Price Percentage of premium Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Ownership percentage Period to register for resale the shares of common stock from the additional issuance, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Register for Resale of Common Stock, Additional Issuances Register for resale of common stock The number of votes for each share held . Number of Votes Number of votes The number of new common stock issued in the conversion of each stock. Conversion of Stock, Common Stock Issued for Each Share Converted Number of common stock issued upon conversion of each share Maximum percent of common stock that can be owned after conversion of preferred stock. Threshold Percentage For Conversion Threshold percentage for conversion Preferred Stock, Liquidation Preference Per Share Liquidation preference per share Conversion of Stock, Shares Converted Number of shares elected to convert Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to 2018 stock option and grant plan. 2018 Stock Option and Grant Plan Vesting [Axis] Vesting [Domain] Vesting upon first anniversary Vesting in equal quarterly installments Title of Individual [Axis] Title of Individual [Domain] Represents information pertaining to non executive directors. Non Executive Directors Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Percentage of options vesting Number of quarterly installments of vesting of share-based compensation awards. Share-based Compensation Arrangement by Share-based Payment Award, Vesting, Number of Quarterly Installment Number of quarterly installments for vesting Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Ending balance Beginning balance Options outstanding Represents information pertaining to 2019 stock option and incentive plan. 2019 Stock Option and Incentive Plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number stock option authorized Represents the percentage of the then outstanding number of shares which will be the cumulative annual increase in issuance under the stock incentive plan. Stock Incentive Plan Arrangement, Cumulative Annual Increase In Issuance Of Percentage Of Outstanding Shares Number of shares outstanding were cumulatively increased Number of common stock entitled for each option upon the exercise of the option. Share-based Payment Arrangement, Option, Number of Common Stock Entitled for Each Option Number of common stock entitled for each option upon the exercise of the option Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used in the Black-Scholes option-pricing model Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Option exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Option unvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Averaged Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Ending balance Beginning balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted Exercise price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Option exercisable Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Option unvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, option exercisable Weighted average remaining contractual term for non- vested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'. Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, option unvested Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, ending balance Aggregate Intrinsic Value, beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, option exercisable Amount by which current fair value of underlying stock exceeds exercise price of non- vested options. Share-based Compensation Arrangement by Share-based Payment Award, Options, Non-Vested, Aggregate Intrinsic Value Aggregate Intrinsic Value, option unvested The fair value per common stock used for calculating the intrinsic values. Share-based Compensation Arrangement by Share-based Payment Award, Options, Fair Value used for Calculating Intrinsic Values Fair value per common stock used for calculating intrinsic values Proceeds from Stock Options Exercised Cash received from option exercise under share-based payment arrangements Award Type [Axis] Equity Award [Domain] Common Stock Awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based awards granted Fair value of share-based awards granted during the period. Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Total Fair Value Aggregate fair value of share-based awards granted The weighted average grant date fair value price of shares issued at grant date. Share-based Compensation Arrangement by Share-based Payment Award, Weighted Average Grant Date Fair Value Grant date fair value per share Income Statement Location [Axis] Income Statement Location [Domain] Research and development expenses General and Administrative Expense Amount of income tax benefits recorded for the net operating losses incurred. Income Tax benefits, Net Operating Losses Incurred Income tax benefits for the net operating losses incurred Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Leases Operating Lease, Liability Outstanding operating lease obligations Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate on operating lease liabilities (as a percent) Operating Lease, Weighted Average Remaining Lease Term Weighted average lease term remaining on operating lease liabilities (in years) Contractual Obligation Non-cancellable obligations Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year 2022 deliverables (remaining three months) Contractual Obligation, Due in Next Fiscal Year 2023 deliverables Contractual Obligation, Due in Second Year 2024 deliverables The amount of licensing fees from intellectual property licenses. Licensing fees, Intellectual Property Licenses Licensing fees from intellectual property licenses Net Income (Loss) Attributable to Parent [Abstract] Numerator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator: Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS), before taking into consideration Series A convertible preferred shares outstanding converted into common stock. Weighted Average Number of Shares Outstanding, Basic and Diluted, Before Conversion Weighted-average common shares outstanding, basic and diluted Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock. Weighted-average Series A convertible Preferred Shares Outstanding, Converted into Common Stock Weighted-average Series A convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock. Weighted-average Series A One convertible Preferred Shares Outstanding, Converted into Common Stock Weighted-average Series A-1 convertible preferred shares outstanding, basic and diluted, presented as if converted into common stock Weighted Average Number of Shares Outstanding, Basic Total number of shares used to calculate net loss per share, basic Weighted Average Number of Shares Outstanding, Diluted Total number of shares used to calculate net loss per share, diluted Convertible Preferred Stock, Shares Issued upon Conversion Number of common stock issued upon conversion of each share of Preferred Stock Number of common stock issuable upon conversion of Series A-1 convertible preferred stock. Convertible Preferred Stock, SeriesA One Shares Issuable upon Conversion Number of common stock issuable upon conversion of Series A-1 convertible preferred stock Ratio applied to the conversion of stock. Shares Conversion Ratio Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Options Restricted stock units Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent event Represents information related to Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. Roche collaboration agreement Subsequent Event [Line Items] Subsequent Events